<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>polypharmacy in elderly &#8211; Science</title>
	<atom:link href="https://scienmag.com/tag/polypharmacy-in-elderly/feed/" rel="self" type="application/rss+xml" />
	<link>https://scienmag.com</link>
	<description></description>
	<lastBuildDate>Thu, 16 Jul 2026 17:10:15 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1</generator>

<image>
	<url>https://scienmag.com/wp-content/uploads/2024/07/cropped-scienmag_ico-32x32.jpg</url>
	<title>polypharmacy in elderly &#8211; Science</title>
	<link>https://scienmag.com</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">73899611</site>	<item>
		<title>Medication Complexity and Risk of Rehospitalization in Older Chronic Kidney Disease Patients</title>
		<link>https://scienmag.com/medication-complexity-and-risk-of-rehospitalization-in-older-chronic-kidney-disease-patients/</link>
		
		<dc:creator><![CDATA[Jerry Hayes]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 17:10:15 +0000</pubDate>
				<category><![CDATA[Medicine]]></category>
		<category><![CDATA[chronic kidney disease management]]></category>
		<category><![CDATA[impact of medication complexity on health outcomes]]></category>
		<category><![CDATA[medication adherence challenges]]></category>
		<category><![CDATA[medication burden and patient safety]]></category>
		<category><![CDATA[Medication regimen complexity]]></category>
		<category><![CDATA[observational study on medication complexity]]></category>
		<category><![CDATA[older adults with chronic kidney disease]]></category>
		<category><![CDATA[polypharmacy in elderly]]></category>
		<category><![CDATA[practical factors influencing medication adherence]]></category>
		<category><![CDATA[prognostic value of medication regimen complexity]]></category>
		<category><![CDATA[rehospitalization risk]]></category>
		<category><![CDATA[retrospective cohort study]]></category>
		<guid isPermaLink="false">https://scienmag.com/medication-complexity-and-risk-of-rehospitalization-in-older-chronic-kidney-disease-patients/</guid>

					<description><![CDATA[A new study in BMC Geriatrics adds evidence to a growing debate over how medication burden affects outcomes in vulnerable patients. Focusing on older adults living with chronic kidney disease, the researchers asked a practical clinical question: does the complexity of a patient’s medication regimen predict whether they will return to the hospital? Using a [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>A new study in BMC Geriatrics adds evidence to a growing debate over how medication burden affects outcomes in vulnerable patients. Focusing on older adults living with chronic kidney disease, the researchers asked a practical clinical question: does the complexity of a patient’s medication regimen predict whether they will return to the hospital?</p>
<p>Using a retrospective cohort design, the team evaluated medication regimen complexity alongside rehospitalization outcomes. Rather than treating “number of prescriptions” as the sole factor, the analysis emphasized the multifaceted nature of regimen complexity—such as dosing schedules and the practical effort required to follow therapy correctly over time.</p>
<p>The study’s cohort comprised older participants with chronic kidney disease, reflecting a population where polypharmacy is common and physiological changes can alter how drugs behave in the body. In this setting, even small adherence difficulties can cascade into worsening symptoms, preventable complications, and ultimately emergency care.</p>
<p>Technically, the researchers linked regimen complexity measures to rehospitalization risk, controlling for relevant patient characteristics that could also influence outcomes. This approach strengthens the causal interpretation typical of observational studies, even though it cannot fully replace randomized trials.</p>
<p>Clinically, the results suggest that greater regimen complexity is not merely an administrative burden; it may carry measurable prognostic value for near-term health trajectories. For older adults, complex schedules can increase the probability of missed doses, dosing errors, or confusion between medications—factors that can undermine treatment goals.</p>
<p>The implications extend beyond adherence alone. Medication complexity can interact with kidney function decline, drug–drug interactions, and fluctuating tolerability, all of which are common in chronic kidney disease management. When these pressures accumulate, the risk of rehospitalization may rise.</p>
<p>For clinicians, the findings reinforce the value of medication reviews and regimen simplification strategies, including deprescribing where appropriate and consolidating dosing schedules when possible. For health systems, it supports integrating complexity assessments into routine geriatric and nephrology care pathways.</p>
<p>Taken together, the work positions medication regimen complexity as a modifiable risk signal. If future prospective studies confirm these patterns, clinicians could use complexity metrics to identify patients most likely to benefit from targeted interventions—potentially reducing avoidable readmissions.</p>
<p><strong>Subject of Research</strong>: Older adults with chronic kidney disease; medication regimen complexity and rehospitalization.</p>
<p><strong>Article Title</strong>: Evaluation of medication regimen complexity and rehospitalization in older adults with chronic kidney disease: a retrospective cohort study.</p>
<p><strong>Article References</strong>: Albayrak, A., Başarır, C.N. &amp; Altuntaş, A. (2026). BMC Geriatrics. https://doi.org/10.1186/s12877-026-07986-7</p>
<p><strong>Image Credits</strong>: AI Generated</p>
<p><strong>DOI</strong>: 10.1186/s12877-026-07986-7</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">173207</post-id>	</item>
		<item>
		<title>Reevaluating Dementia Medications in Primary Care Settings</title>
		<link>https://scienmag.com/reevaluating-dementia-medications-in-primary-care-settings/</link>
		
		<dc:creator><![CDATA[Cassandra Pierce]]></dc:creator>
		<pubDate>Tue, 03 Feb 2026 04:28:07 +0000</pubDate>
				<category><![CDATA[Medicine]]></category>
		<category><![CDATA[Accountable Care Organizations and dementia]]></category>
		<category><![CDATA[adverse effects of dementia medications]]></category>
		<category><![CDATA[cognitive decline and medication effects]]></category>
		<category><![CDATA[dementia medication management]]></category>
		<category><![CDATA[deprescribing practices in dementia care]]></category>
		<category><![CDATA[evidence-based dementia treatment]]></category>
		<category><![CDATA[improving dementia care strategies]]></category>
		<category><![CDATA[medication adherence vs deprescribing]]></category>
		<category><![CDATA[polypharmacy in elderly]]></category>
		<category><![CDATA[primary care for dementia patients]]></category>
		<category><![CDATA[quality of life for dementia patients]]></category>
		<category><![CDATA[tailored medication review for dementia]]></category>
		<guid isPermaLink="false">https://scienmag.com/reevaluating-dementia-medications-in-primary-care-settings/</guid>

					<description><![CDATA[In recent years, the focus on health care for those living with dementia has grown significantly, particularly in the realm of medication management. A paradigm shift is underway, where the necessity of balancing therapeutic benefits with potential adverse effects merits careful scrutiny. This evolving landscape is explored in a recent qualitative study titled &#8220;Champion-Led Deprescribing [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>In recent years, the focus on health care for those living with dementia has grown significantly, particularly in the realm of medication management. A paradigm shift is underway, where the necessity of balancing therapeutic benefits with potential adverse effects merits careful scrutiny. This evolving landscape is explored in a recent qualitative study titled &#8220;Champion-Led Deprescribing for Persons with Dementia in Primary Care,&#8221; which is poised to influence how medical professionals approach prescribing practices for this vulnerable population.</p>
<p>The study, originating from an in-depth examination within various Accountable Care Organizations (ACOs), places a spotlight on a critical aspect of dementia care: deprescribing. Unlike the traditional approach emphasizing medication adherence, deprescribing encourages a tailored review of the necessity and appropriateness of each medication an individual with dementia is taking. This approach is bolstered by growing evidence that many patients are often prescribed medications that may contribute little to their quality of life or could even exacerbate cognitive decline.</p>
<p>Dementia patients frequently endure polypharmacy—concurrent use of multiple medications—which can lead to a slew of complications, including increased confusion, falls, and hospitalizations. As the study highlights, the sheer volume of medications prescribed to these individuals often exceeds what is necessary or appropriate for managing their symptoms. Hence, the role of healthcare providers in scrutinizing medication regimens cannot be overstated, as unnecessary prescriptions can lead to adverse outcomes despite the initial intention to provide relief.</p>
<p>One of the groundbreaking aspects of this research is its focus on champion-led deprescribing initiatives. These champions, often drawn from multidisciplinary teams within primary care settings, empower both patients and caregivers in the decision-making process concerning medication management. Their role extends beyond mere oversight; they serve as advocates who navigate the complex interplay between dementia care needs and medication effects. By fostering open lines of communication, these champions cultivate an environment where caregivers feel supported and patients can voice their concerns about their treatment plans.</p>
<p>The research taps into the qualitative experiences of participants, revealing insights into the fears and apprehensions that accompany the idea of reducing or stopping medications. Many caregivers express deep-rooted concerns about the potential for worsening symptoms or the perceived risks of altering an established regimen. The study meticulously documents these emotional and psychosocial aspects, showcasing the need for compassion in the deprescribing process.</p>
<p>A vital component of successful deprescribing is education. The study underscores the importance of providing both caregivers and patients with comprehensive information regarding the rationale behind changes in medication. Patients should understand that the goal of deprescribing is not to deprive them of needed care but rather to enhance their overall well-being and operational functionality. Facilitating discussions around medication efficacy allows for more personalized care plans that reflect the unique needs of each individual.</p>
<p>Another significant finding of the research points to the existing barriers that healthcare providers face in implementing deprescribing practices effectively. Institutional resistance, time constraints, and fears of litigation often hinder practitioners from feeling empowered to question established prescribing habits. The study advocates for institutional reforms that champion more flexible prescribing guidelines, creating a culture that embraces patient-centered care as a cornerstone of dementia management.</p>
<p>Furthermore, the study reinforces the critical aspect of follow-up assessments after deprescribing medications. Ongoing evaluations not only help in alleviating the fears of caregivers and patients but also provide the medical team with insights into how changes in medication affect overall health outcomes. Regular monitoring allows for the potential reassessment of medications, ensuring that patients receive only what is necessary for their well-being throughout the course of their condition.</p>
<p>The research also reveals a glimmer of hope through patient-centric initiatives that empower individuals with dementia to engage actively in their health care decisions. By prioritizing patients&#8217; preferences and values, healthcare teams can cultivate trust and establish stronger relationships with their patients and their families. This mutual respect fosters an environment conducive to candid discussions about the potential trade-offs of continuing versus discontinuing medications.</p>
<p>In conclusion, the study emerges as a seminal contribution to the literature surrounding dementia care, particularly as it relates to the practice of deprescribing. The advocacy for champion-led initiatives within primary care settings encapsulates a modern approach to medication management, transcending traditional paradigms focused solely on compliance. As healthcare systems evolve, the importance of personalized, patient-centered strategies will only grow, heralding a new era of empathetic and judicious care for individuals with dementia.</p>
<p>The implications of this study extend beyond its immediate findings, inviting ongoing discourse in both clinical and academic circles regarding best practices in dementia management. Peer-reviewed outcomes will hopefully inspire further research collaboration and innovation in educational paradigms that ensure the well-being of individuals battling cognitive decline. With efforts to understand the intricacies of deprescribing, the healthcare community can address the urgent need for improvement in the quality of life for those living with dementia.</p>
<p><strong>Subject of Research</strong>: Deprescribing for Persons with Dementia in Primary Care<br />
<strong>Article Title</strong>: Champion-Led Deprescribing for Persons with Dementia in Primary Care: A Qualitative Study in Accountable Care Organizations<br />
<strong>Article References</strong>: Tabata-Kelly, M., Palazzo, L.G., Perloff, J. et al. Champion-Led Deprescribing for Persons with Dementia in Primary Care: A Qualitative Study in Accountable Care Organizations. J GEN INTERN MED (2026). <a href="https://doi.org/10.1007/s11606-026-10234-8">https://doi.org/10.1007/s11606-026-10234-8</a><br />
<strong>Image Credits</strong>: AI Generated<br />
<strong>DOI</strong>: <a href="https://doi.org/10.1007/s11606-026-10234-8">https://doi.org/10.1007/s11606-026-10234-8</a><br />
<strong>Keywords</strong>: Dementia, Deprescribing, Primary Care, Polypharmacy, Patient-Centric Care, Qualitative Study, Healthcare Innovation</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">134146</post-id>	</item>
	</channel>
</rss>
